Compass Associates
Multi-award-winning recruitment consultancy dedicated to the independent Health, Social Care and Children's Services sectors.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
AstraZeneca and Daiichi Sankyo’s HER2-targeting antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval in the US for the treatment of locally advanced/metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.